Bristol-Myers Squibb appoints Icon for clinical development services
31 August 2011 00:00 in Pharmaceutical Company Product News
Bristol-Myers Squibb has selected Icon to offer support and expertise to assist its early stage clinical development programmes.
The biopharmaceutical services provider has been chosen as a preferred provider for full-service clinical pharmacology and exploratory clinical studies, building on a partnership that has been in place since June 2010.
A range of clinical trial services will be offered to Bristol-Myers Squibb via Icon's clinical pharmacology units in Manchester in the UK and San Antonio and Omaha in the US, thus improving productivity and cost-effectiveness.
Among the specific functions Icon will fulfil are protocol design and development, project management, clinical monitoring and pharmacovigilance.
Dr Mario Rocci, president for Icon Development Solutions, said: "We are pleased that Bristol-Myers Squibb has again chosen Icon to bring greater operational efficiencies and high-quality science to their drug development programmes."
Earlier this week, Bristol-Myers Squibb published clinical research data supporting the efficacy of Eliquis, a treatment for atrial fibrillation-related stroke developed alongside Pfizer.
Other news stories from 31/08/2011
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency